Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Nod For Pfizer’s COVID-19 Oral Treatment

Pfizer Aims For Early 2022 To Deliver First Treatment Courses To Great Britain

Executive Summary

Pfizer’s Paxlovid is the second take-at-home COVID-19 treatment approved for use in the UK.

You may also be interested in...



EU Approves Paxlovid For COVID-19

The European Medicines Agency’s assessment of the oral antiviral combination was conducted under the OPEN Initiative, which involves information sharing among international regulators.

Coronavirus Notebook: Pfizer Files Paxlovid In EU, France Updates Treatment Advice As Omicron Proliferates

NRx Pharmaceuticals has again filed for a US emergency use authorization for aviptadil, this time for critically ill patients with no other options. The UK has said that there is currently no need to give a second booster vaccine.

Merck & Co Makes Case For Molnupiravir After Narrow FDA Nod

US regulators have granted emergency authorization to the antiviral molnupiravir but only for use when "alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate."

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel